Hyderabad, July 22 -- Dr. Reddy's Laboratories Ltd on Wednesday reported a 69 per cent year-on-year decline in consolidated profit after tax (PAT) attributable to equity holders at Rs 443.5 crore for the first quarter ended June 30, 2026, primarily due to lower lenalidomide revenues and the impact of a provision related to semaglutide active pharmaceutical ingredient (API).
The Hyderabad-based pharmaceutical major posted consolidated revenues of Rs 8,070.5 crore, down 5.6 per cent year-on-year but up 7.4 per cent sequentially.
EBITDA stood at Rs 1,008.8 crore, while profit before tax (PBT) came in at Rs 552.6 crore.
The company said the results included an adverse impact of a Rs 239.7 crore provision towards inventory and associated cost...